Bénédicte C.
- Country
- France
- Department
- Gastroenterology
Research Overview
- A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Duvakitug for Maintenance Therapy in Participants with Moderately to Severely Active Crohn’s Disease: A Phase 3, Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 437 of 621 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel diseases, with particular focus on both Crohn's disease and ulcerative colitis in their moderate to severe forms.
- Advanced therapeutic approaches for IBD
- Novel treatment modalities
- Disease activity assessment
The investigator evaluates innovative therapeutic agents for managing inflammatory bowel conditions.
Clinical Innovation
Focuses on investigating induction therapies and maintenance treatments for gastrointestinal disorders, with emphasis on achieving clinical remission and endoscopic response.
- Treatment response evaluation
- Long-term disease management
- Clinical remission strategies
Expertise includes assessment of both subcutaneous and oral therapeutic interventions.
Specialized Therapeutic Areas
Dedicated to exploring post-operative care and disease recurrence prevention, including innovative approaches such as fecal microbiota transplantation.
- Post-surgical management
- Microbiome-based interventions
- Recurrence prevention strategies
Investigates targeted therapies for complex gastrointestinal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.